P/E ratio for Perspective Therapeutics (CATX)
P/E ratio as of May 2024 (TTM): -16.7
According to Perspective Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -16.6989. At the end of 2022 the company had a P/E ratio of -3.57.
P/E ratio history for Perspective Therapeutics from 2005 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -3.57 | -54.21% |
| 2021 | -7.80 | -13.33% |
| 2020 | -9.00 | -12.9% |
| 2019 | -10.3 | 244.44% |
| 2018 | -3.00 | -17.5% |
| 2017 | -3.64 | -31.03% |
| 2016 | -5.27 | -55.13% |
| 2015 | -11.8 | -11.47% |
| 2014 | -13.3 | 245.09% |
| 2013 | -3.85 | -40.83% |
| 2012 | -6.50 | 18.18% |
| 2011 | -5.50 | -26.99% |
| 2010 | -7.53 | 69.29% |
| 2009 | -4.45 | 567.5% |
| 2008 | -0.6667 | -85.07% |
| 2007 | -4.47 | -44.39% |
| 2006 | -8.03 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.